泰林生物
(300813)
| 流通市值：15.19亿 | | | 总市值：24.20亿 |
| 流通股本：7605.11万 | | | 总股本：1.21亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 66,938,979.3 | 348,998,253.03 | 242,467,278.88 | 156,282,129.74 |
| 营业收入 | 66,938,979.3 | 348,998,253.03 | 242,467,278.88 | 156,282,129.74 |
| 二、营业总成本 | 62,864,064.42 | 348,161,065.58 | 236,221,850.45 | 151,988,460.49 |
| 营业成本 | 33,955,877.64 | 197,123,029.57 | 126,295,460.96 | 81,066,133.17 |
| 税金及附加 | 796,995.49 | 5,294,553.55 | 2,583,868.59 | 1,747,028.21 |
| 销售费用 | 7,685,320.31 | 43,057,417.21 | 31,709,097.72 | 20,224,732.28 |
| 管理费用 | 7,914,418.4 | 35,307,464.59 | 22,817,792.06 | 15,946,459.52 |
| 研发费用 | 14,934,663.08 | 62,343,886.04 | 49,454,422.64 | 31,252,149.65 |
| 财务费用 | -2,423,210.5 | 5,034,714.62 | 3,361,208.48 | 1,751,957.66 |
| 其中:利息费用 | - | 14,779,929.65 | 11,545,365.77 | 7,679,788.91 |
| 其中:利息收入 | -2,432,157.58 | 9,734,897.68 | -8,495,802.75 | 5,933,491.68 |
| 加:投资收益 | -3,055.94 | 1,854,833.53 | - | -71,906.25 |
| 资产减值损失(新) | - | -699,372.18 | -204,971.22 | -213,182.2 |
| 信用减值损失(新) | -1,274,589.87 | -1,507,738.18 | -421,208.24 | -856,724.83 |
| 其他收益 | 1,250,110.86 | 11,913,830.23 | 7,231,506.67 | 4,302,674.23 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 4,047,379.93 | 12,398,740.85 | 12,850,755.64 | 7,454,530.2 |
| 加:营业外收入 | 7,340.66 | 1,142,150.76 | 402,698.36 | 343,973.11 |
| 减:营业外支出 | 535,740.85 | 774,406.6 | 658,181.85 | 589,610.77 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 3,518,979.74 | 12,766,485.01 | 12,595,272.15 | 7,208,892.54 |
| 减:所得税费用 | 191,063.22 | 512,858.29 | 1,995,378.01 | 1,342,713.9 |
| 六、净利润 | 3,327,916.52 | 12,253,626.72 | 10,599,894.14 | 5,866,178.64 |
| 持续经营净利润 | 3,327,916.52 | 12,253,626.72 | 10,599,894.14 | 5,866,178.64 |
| 归属于母公司股东的净利润 | 3,528,154.63 | 13,050,671.23 | 11,314,672.2 | 6,582,050.48 |
| 少数股东损益 | -200,238.11 | -797,044.51 | -714,778.06 | -715,871.84 |
| (一)基本每股收益 | 0.03 | 0.12 | 0.1 | 0.06 |
| (二)稀释每股收益 | 0.03 | 0.12 | 0.14 | 0.1 |
| 九、综合收益总额 | 3,327,916.52 | 12,253,626.72 | 10,599,894.14 | 5,866,178.64 |
| 归属于母公司股东的综合收益总额 | 3,528,154.63 | 13,050,671.23 | 11,314,672.2 | 6,582,050.48 |
| 归属于少数股东的综合收益总额 | -200,238.11 | -797,044.51 | -714,778.06 | -715,871.84 |
| 公告日期 | 2025-04-28 | 2025-04-28 | 2024-10-30 | 2024-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |